FDA Grants Priority Review for ENHERTU Supplement Application
The FDA has granted priority review for the supplemental application of ENHERTU (fam-trastuzumab deruxtecan-nxki) submitted by Daiichi Sankyo.
Asset / Drug
Drug and asset intelligence for ENHERTU with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Enhertu has received FDA approval for two new indications in HER2-positive early breast cancer, both before and after surgery.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.